GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Total Current Assets

Nutriband (Nutriband) Total Current Assets : $1.02 Mil (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nutriband Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Nutriband's total current assets for the quarter that ended in Jan. 2024 was $1.02 Mil.


Nutriband Total Current Assets Historical Data

The historical data trend for Nutriband's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Total Current Assets Chart

Nutriband Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Total Current Assets
Get a 7-Day Free Trial Premium Member Only 0.04 0.31 5.47 2.69 1.02

Nutriband Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.69 1.99 3.27 2.00 1.02

Nutriband Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Nutriband's Total Current Assets for the fiscal year that ended in Jan. 2024 is calculated as

Nutriband's Total Current Assets for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Nutriband  (NAS:NTRB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Nutriband's Liquidation Value for the quarter that ended in Jan. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.493-1.079+0.75 * 0.149+0.5 * 0.169
=-0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutriband Total Current Assets Related Terms

Thank you for viewing the detailed overview of Nutriband's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutriband (Nutriband) Business Description

Traded in Other Exchanges
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401